{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:40:31Z","timestamp":1793299231490,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s40265-020-01288-x","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T10:04:01Z","timestamp":1584007441000},"page":"513-521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":330,"title":["Tazemetostat: First Approval"],"prefix":"10.1007","volume":"80","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"issue":"5","key":"1288_CR1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11899-018-0466-6","volume":"13","author":"JK Lue","year":"2018","unstructured":"Lue JK, Amengual JE. Emerging EZH2 inhibitors and their application in lymphoma. Curr Hematol Malig Rep. 2018;13(5):369\u201382.","journal-title":"Curr Hematol Malig Rep."},{"key":"1288_CR2","unstructured":"Histone. 2014. https:\/\/www.nature.com\/scitable\/definition\/histones-57\/. Accessed 12 Feb 2020."},{"issue":"7","key":"1288_CR3","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1080\/10428194.2018.1430795","volume":"59","author":"N Gulati","year":"2018","unstructured":"Gulati N, Beguelin W, Giulino-Roth L. Enhancer of zeste homolog 2 (EZH2) inhibitors. Leuk Lymphoma. 2018;59(7):1574\u201385.","journal-title":"Leuk Lymphoma."},{"key":"1288_CR4","unstructured":"Epizyme. Epizyme announces exercise of $50 million option with Royalty Pharma and highlights key 2020 initiatives to build long-term value [media release]. http:\/\/www.epizyme.com. Accessed 6 Jan 2020."},{"key":"1288_CR5","unstructured":"Epizyme. Epizyme reacquires global rights from Eisai for first-in-class EZH2 inhibitor EPZ-6438 [media release]. 13 Mar 2015. http:\/\/www.epizyme.com."},{"key":"1288_CR6","unstructured":"US FDA. FDA approves first treatment option specifically for patients with epithelioid sarcoma, a rare soft tissue cancer. 2020. http:\/\/www.fda.gov\/. Accessed 29 Jan 2020."},{"key":"1288_CR7","unstructured":"US FDA. FDA approves tazemetostat for advanced epithelioid sarcoma. 2020. https:\/\/www.fda.gov\/. Accessed 29 Jan 2020."},{"key":"1288_CR8","unstructured":"Epizyme Inc. Tazverik (tazemetostat) tablets, for oral use: US prescribing information. 2020. http:\/\/www.fda.gov\/. Accessed 29 Jan 2020."},{"key":"1288_CR9","unstructured":"Epizyme. Epizyme announces FDA acceptance of New Drug Application for filing with Priority Review for TAZVERIK\u2122 (tazemetostat) for the treatment of follicular lymphoma [media release]. 14 Feb 2020. http:\/\/www.epizyme.com\/."},{"key":"1288_CR10","unstructured":"US FDA. Orphan drug designations and approvals. 2017. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/index.cfm. Accessed 13 Feb 2020."},{"key":"1288_CR11","unstructured":"European Medicines Agency. Public summary of opinion on orphan designation: tazemetostat for the treatment of diffuse large B-cell lymphoma. 2018. http:\/\/www.ema.europa.eu\/. Accessed 29 Jan 2020."},{"key":"1288_CR12","unstructured":"European Medicines Agency. Public summary of opinion on orphan designation: tazemetostat for the treatment of follicular lymphoma. 2018. http:\/\/www.ema.europa.eu\/. Accessed 29 Jan 2020."},{"key":"1288_CR13","unstructured":"European Medicines Agency. Public summary of opinion on orphan designation: tazemetostat for the treatment of malignant mesothelioma. 2018. http:\/\/www.ema.europa.eu\/. Accessed 29 Jan 2020."},{"key":"1288_CR14","unstructured":"Epizyme. Epizyme reports business progress and second quarter 2019 results [media release]. 9 Aug 2019. http:\/\/www.epizyme.com."},{"key":"1288_CR15","unstructured":"Epizyme. Epizyme enters worldwide strategic partnership with Eisai for cancer therapeutics targeting EZH2 epigenetic enzyme [media release]. 11 Mar 2011. http:\/\/www.epizyme.com."},{"key":"1288_CR16","unstructured":"Epizyme. Epizyme initiates collaboration on combination trial of tazemetostat and Tecentriq(TM) (atezolizumab) for treatment of non-Hodgkin lymphoma [media release]. 22 Jun 2016. http:\/\/www.epizyme.com."},{"key":"1288_CR17","unstructured":"Epizyme. Epizyme expands clinical collaboration to study tazemetostat and TECENTRIQ(R) combination in NSCLC [media release]. http:\/\/www.epizyme.com. Accessed 26 Jun 2017."},{"key":"1288_CR18","unstructured":"Epizyme. Epizyme expands clinical programs through Cooperative Research and Development Agreements with the National Cancer Institute [media release]. 2 Nov 2016. http:\/\/www.epizymeclinicaltrials.com."},{"key":"1288_CR19","unstructured":"Epizyme. Epizyme establishes agreements for up to $270 Million in funding to support tazemetostat commercialization and pipeline advancement [media release]. 5 Nov 2019. http:\/\/www.epizyme.com."},{"issue":"12","key":"1288_CR20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nrc.2016.83","volume":"16","author":"I Comet","year":"2016","unstructured":"Comet I, Riising EM, Leblanc B, et al. Maintaining cell identity: PRC2-mediated regulation of transcription and cancer. Nat Rev Cancer. 2016;16(12):803\u201310.","journal-title":"Nat Rev Cancer."},{"issue":"10","key":"1288_CR21","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1097\/PAS.0b013e31822b325b","volume":"35","author":"TJ Hollmann","year":"2011","unstructured":"Hollmann TJ, Hornick JL. INI1-deficient tumors: diagnostic features and molecular genetics. Am J Surg Pathol. 2011;35(10):e47\u201363.","journal-title":"Am J Surg Pathol."},{"issue":"19","key":"1288_CR22","doi-asserted-by":"publisher","first-page":"7922","DOI":"10.1073\/pnas.1303800110","volume":"110","author":"SK Knutson","year":"2013","unstructured":"Knutson SK, Warholic NM, Wigle TJ, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci USA. 2013;110(19):7922\u20137.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"4","key":"1288_CR23","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","volume":"13","author":"SK Knutson","year":"2014","unstructured":"Knutson SK, Kawano S, Minoshima Y, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther. 2014;13(4):842\u201354.","journal-title":"Mol Cancer Ther."},{"issue":"5","key":"1288_CR24","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1158\/1535-7163.MCT-16-0678","volume":"16","author":"E Chan-Penebre","year":"2017","unstructured":"Chan-Penebre E, Armstrong K, Drew A, et al. Selective killing of SMARCA2- and SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic type cells by inhibition of EZH2: in vitro and in vivo preclinical models. Mol Cancer Ther. 2017;16(5):850\u201360.","journal-title":"Mol Cancer Ther."},{"key":"1288_CR25","doi-asserted-by":"crossref","unstructured":"Motwani V, Brach D, Pantano C, et al. Synergistic activity of tazemetostat in combination with androgen signaling inhibitors in preclinical models of prostate cancer demonstrates potential for clinical expansion [abstract no. B011]. Mol Cancer Ther. 2019;18(12 Suppl).","DOI":"10.1158\/1535-7163.TARG-19-B011"},{"key":"1288_CR26","doi-asserted-by":"crossref","unstructured":"Hood TL, Cosmopoulos K, Drew A, et al. Opportunity for therapeutic expansion in mantle cell lymphoma: tazemetostat combination synergy status in preclinical MCL models [abstract no. 808\/18]. In: 109th Annual Meeting of the American Association for Cancer Research. 2018.","DOI":"10.1158\/1538-7445.AM2018-808"},{"key":"1288_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15007","author":"H Fu","year":"2020","unstructured":"Fu H, Cheng L, Sa R, et al. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAFV600E by synergistically decreasing global trimethylation of H3K27. J Cell Mol Med. 2020. https:\/\/doi.org\/10.1111\/jcmm.15007.","journal-title":"J Cell Mol Med."},{"issue":"5","key":"1288_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","volume":"19","author":"A Italiano","year":"2018","unstructured":"Italiano A, Soria JC, Toulmonde M, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018;19(5):649\u201359.","journal-title":"Lancet Oncol."},{"key":"1288_CR29","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT02601950. 2019. http:\/\/clinicaltrials.gov\/. Accessed 20 Feb 2020."},{"issue":"Suppl 8","key":"1288_CR30","doi-asserted-by":"publisher","first-page":"viii580","DOI":"10.1093\/annonc\/mdy299.010","volume":"29","author":"S Stacchiotti","year":"2018","unstructured":"Stacchiotti S, Blay JY, Jones RL, et al. A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950) [abstract no. 1611PD]. Ann Oncol. 2018;29(Suppl 8):viii580.","journal-title":"Ann Oncol"},{"issue":"15 Suppl","key":"1288_CR31","doi-asserted-by":"publisher","first-page":"11003","DOI":"10.1200\/JCO.2019.37.15_suppl.11003","volume":"37","author":"S Stacchiotti","year":"2019","unstructured":"Stacchiotti S, Schoffski P, Jones R, et al. Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950) [abstract no 11003]. J Clin Oncol. 2019;37(15 Suppl):11003.","journal-title":"J Clin Oncol."},{"issue":"Suppl 8","key":"1288_CR32","doi-asserted-by":"publisher","first-page":"viii580","DOI":"10.1093\/annonc\/mdy299.011","volume":"29","author":"RL Jones","year":"2018","unstructured":"Jones RL, Blay JY, Agulnik M, et al. A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort) (NCT02601950) [abstract no. 1612PD]. Ann Oncol. 2018;29(Suppl 8):viii580\u20131.","journal-title":"Ann Oncol."},{"issue":"15 Suppl","key":"1288_CR33","doi-asserted-by":"publisher","first-page":"11057","DOI":"10.1200\/JCO.2017.35.15_suppl.11057","volume":"35","author":"P Schoffski","year":"2017","unstructured":"Schoffski P, Agulnik M, Stacchiotti S, et al. Phase 2 multicenter study of the EZH2 inhibitor tzemetostat in adults with synovial sarcoma (NCT02601950) [abstract no. 11057]. J Clin Oncol. 2017;35(15 Suppl):11057.","journal-title":"J Clin Oncol."},{"key":"1288_CR34","doi-asserted-by":"crossref","unstructured":"Ribrag V, Morschhauser F, McKay P, et al. Interim results from an ongoing phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) [abstract no. 4196]. Blood. 2018;132(Suppl 1).","DOI":"10.1182\/blood-2018-99-113411"},{"key":"1288_CR35","doi-asserted-by":"crossref","unstructured":"Morschhauser F, Tilly H, Chaidos A, et al. Phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory follicular lymphoma [abstract no. 123]. Blood. 2019;134(Suppl 1).","DOI":"10.1182\/blood-2019-128096"},{"issue":"15 Suppl","key":"1288_CR36","doi-asserted-by":"publisher","first-page":"8515","DOI":"10.1200\/JCO.2018.36.15_suppl.8515","volume":"36","author":"MG Zauderer","year":"2018","unstructured":"Zauderer MG, Szlosarek P, Le Moulec S, et al. Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R\/R) malignant mesothelioma (MM) with BAP1 inactivation [abstract no. 8515]. J Clin Oncol. 2018;36(15 Suppl):8515.","journal-title":"J Clin Oncol."},{"issue":"Suppl 2","key":"1288_CR37","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/hon.203_2631","volume":"37","author":"ML Palomba","year":"2019","unstructured":"Palomba ML, Cartron G, Popplewell L, et al. Safety and clinical activity of atezolizumab in combination with tazemetostat in relapsed or refractory diffuse large B-cell lymphoma: primary analysis of a phase 1b study [abstract no. 493]. Hematol Oncol. 2019;37(Suppl 2):517\u20139.","journal-title":"Hematol Oncol."},{"key":"1288_CR38","unstructured":"US FDA. Briefing document for the December 18, 2019 US FDA Oncologic Drugs Advisory Committee Meeting: Tazemetostat. 2019. https:\/\/www.fda.gov\/media\/133573\/download. Accessed 2 Mar 2020."},{"key":"1288_CR39","unstructured":"Epizyme. Epizyme announces FDA filing acceptance of New Drug Application and Priority Review for tazemetostat for the treatment of epithelioid sarcoma [media release]. http:\/\/www.epizyme.com. Accessed 26 Jul 2019."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01288-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-020-01288-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01288-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T20:02:50Z","timestamp":1615492970000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-020-01288-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,12]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1288"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01288-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,12]]},"assertion":[{"value":"12 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sheridan Hoy is a salaried employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}